AMOEBA: Corporate governance change and review of the company’s growth strategy
AMOEBA: Corporate governance change and review of the company’s growth strategy
Chassieu (France), Feb.5, 2024 – 8:45am – AMOÉBA (FR0011051598 – ALMIB), AMOÉBA
(FR0011051598 – ALMIB) an industrial biotech in pre-commercialization* specialized in the treatment
of microbiological risk, developing an anti-aging cosmetic ingredient, a biocontrol agent for crop
treatment in agriculture that has obtained a marketing authorization in the United States and a
biological biocide that has also obtained a marketing authorization in the United States for use in
closed cooling systems, announces additional information following a change in governance, and a
review of the company’s growth focus.
Reminder of the change in governance
During its meeting on 14 December 2023, Amoéba’s Board of Directors decided to change the
Company’s mode of governance, resulting in the automatic termination of Fabrice Plasson’s
appointments as Chairman of the Board of Directors and Chief Executive Officer. The Board of Directors
unanimously appointed Benoit Villers, founder and Managing Partner of Nice & Green SA, and former
General Sales Manager of the Barry Callebaut Group, as Chairman of the Board of Directors. Benoit
Villers was proposed by Nice & Green SA, which is the company’s largest shareholder with a 29.4%
stake.
The Board of Directors also appointed Jean-François Doucet, previously Deputy Managing Director, to
the position of Managing Director of the company. Jean-François Doucet has extensive experience in
auditing, consulting, and financial management, gained in international companies.
Review of business development guidelines
At the initiative of its new Chairman and in agreement with the Managing Director and the Board of
Directors, Amoéba has initiated a complete review of its development priorities. The purpose is to
shorten the time needed to generate positive operating cash flow. As a result, we are focusing our
business development on products and markets offering the best returns and the fastest time to
market.
With the aim of focusing on high-margin rather than high-volume activities, it is already envisaged that
the production planned for the short and medium term will be met by extending production capacity
at Chassieu, the company’s current head office. The Board of Directors has therefore decided to put
on hold the construction of the Cavaillon plant, the financing for which has not yet been finalised, until
such time as the sales generated from Chassieu provide sufficient operating cash flow.
Amoéba intends to announce its new action plan in the nearest future, detailing its new directions
aimed at optimising the exploitation of the scientific assets developed and authorised in recent years.